Clinical Experience of Lorlatinib ALK+ NSCLC Patients
Dr. Kim discusses her experience with lorlatinib in real-world settings for ALK+ NSCLC, highlighting both the benefits and challenges of incorporating it into clinical practice.
Overview of Current Treatment Landscape of ALK Inhibitors
Dr. Garon describes the current treatment landscape for metastatic ALK+ NSCLC and explores alternative treatment options that could have been considered for these patients.
Overview of Efficacy of Lorlatinib in the Treatment of ALK+ NSCLC
Dr. Kim provides an overview of the clinical evidence supporting lorlatinib as a first-line therapy for ALK+ metastatic NSCLC, focusing on the key efficacy outcomes from the phase 3 CROWN trial.
Barriers and Challenges in Biomarker Testing for ALK+ NSCLC
Dr. Garon discusses the factors that make a patient a strong candidate for ALK inhibitor therapy in ALK+ NSCLC, the importance of biomarker testing in guiding treatment selection, and his approach to testing along with challenges encountered, especially in community settings.
Evaluating Treatment Options of EGFR Inhibitors
Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.
Clinical Experience of Amivantamab in EGFR+ NSCLC Patients
Dr. Kim shares his clinical experience with amivantamab in real-world practice for EGFR+ NSCLC, discussing both the benefits and challenges of incorporating it into treatment protocols.
Overview of FLAURA and MARIPOSA-2 Clinical Trials
Dr. Kim reviews key clinical evidence from the FLAURA trial for osimertinib as a first-line therapy in EGFR+ metastatic NSCLC and discusses the MARIPOSA 2 trial supporting amivantamab with chemotherapy as the preferred second-line option.
The Impact of Molecular Testing on Treatment Choices for NSCLC
A discussion with Dr. Garon highlights patient selection for EGFR inhibitor therapy in EGFR+ NSCLC, emphasizing the critical role of biomarker testing, testing approaches, and overcoming barriers in community settings.
Robert’s Journey With EGFR+ Metastatic NSCLC
The video segment profiles a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.
Face-Off: Award Presentation Ceremony
Following a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.
Treatment Options for Patients with EGFRm NSCLC
Experts on non–small cell lung cancer reflect on clinical trial data to weigh treatment options for patients with EGFR-mutated non–small cell lung cancer.
Will Neo-Adjuvant Therapies Replace Surgery plus Adjuvant Treatment for Resectable NSCLC?
Jyoti D. Patel, MD, and Rajat Thawani, MBBS, tackle the question of whether neoadjuvant therapies will replace surgery plus adjuvant treatment for patients with resectable non–small cell lung cancer.
Patient Case: KRAS G12C Non–Small Cell Lung Cancer
Robert B. Cameron, MD, PhD, offers insights on a patient with KRAS G12C non–small cell lung cancer.
Clinical Scenario: A PD-L1-Low Patient with NSCLC
Focusing on PD-L1-low NSCLC, Faith Abodunrin, MD, discusses the decision to rechallenge with immunotherapy.
Patient Profile: A 57-Year-Old Woman with NSCLC
Jyoti Patel, MD, presents the case of a patient with EGFR-mutated non–small cell lung cancer requiring treatment following osimertinib.
Patient Case: A 76-Year-Old Woman with ROS1+ Metastatic NSCLC
Initiating a conversation on patient cases, Divya Gupta, MD, presents the profile of a 76-year-old woman with ROS1+ metastatic non–small cell lung cancer.
Amivantamab plus Lazertinib in Atypical EGFR-mutated Advanced NSCLC: Results from CHRYSALIS-2
Divya Gupta, MD, presents data from CHRYSALIS-2 focused on amivantamab plus lazertinib in atypical EGFR-mutated advanced non–small cell lung cancer.
Osimertinib for EGFRm Stage III Unresectable NSCLC: The LAURA Trial
Robert B. Cameron, MD, PhD, reviews data from the LAURA trial investigating osimertinib in patients with EGFR-mutated stage III unresectable NSCLC.
Focusing on the CROWN study, Faith Abodunrin, MD, discusses the role of lorlatinib in the treatment of patients with non–small cell lung cancer.
BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in TKI-naïve ALK-rearranged Metastatic NSCLC
Laila Gharzai, MD, discusses findings from the BRIGHTSTAR trial which evaluated brigatinib in TKI-naïve patients with ALK-rearranged metastatic non–small cell lung cancer.
Introduction of the Non–Small Cell Lung Cancer Face-Off
Joshua K. Sabari, MD, introduces a Face-Off program in which Northwestern University and the University of Chicago will present data and discuss treatment practices in non–small cell lung cancer.